A raw material for a gummy composition, and a gummy candy composed of the gummy composition, contain pyroglutamic acid, preferably in an amount of 0.08 mass % to 1.5 mass %. By adding pyroglutamic acid, the gummy candy has an improved melt-in-the-mouth feeling, while also being non-adhesive and soft, and having improved flavor release during chewing.

The invention relates to a solid, particulate, urea-based composition comprising urea in particulate form and a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT), wherein the urea-based composition is further characterized in that it comprises one or more alkaline or alkaline-forming inorganic compounds. The composition according to the invention has been stabilized against the degradation of a urease inhibitor of the type phosphoric triamide, in particular N-(n-butyl) thiophosphoric triamide (nBTPT) in the presence of urea. The invention further relates to a method for the manufacture of the claimed solid, particulate, urea-based composition.

The present invention relates to compounds and compositions comprising said compounds, for use in the treatment of ADCY5-related dyskinesia.

The present invention aims to provide a novel composition for competitively inhibiting an orexin receptor, which can inhibit binding of orexin to its receptor, and a method of inhibiting binding of orexin to its receptor. The present invention relates to, for example, a composition for competitively inhibiting an orexin receptor, containing pyrroloquinoline quinone or a salt thereof as an active ingredient.

The invention relates to beverages including an active emulsion and a blank emulsion, wherein the blank emulsion is used as a sacrificial agent to retain the active emulsion's potency within an infused beverage.

The present invention relates to a method for preventing oxidation of polyphenols, materials thereof, and uses thereof, and more particularly, it relates to a method of preventing oxidation of catechins by treating catechins with aptamers, aptamers having such activity with preventing oxidation of catechins, and it relates to its application to various fields such as cosmetics, foods, and pharmaceuticals using the aptamer. The aptamer of the present invention has an antioxidant effect of catechins, so the aptamer of the present invention can be applied in various fields such as cosmetics, foods, and pharmaceuticals that require inhibition of oxidation of catechins.

Provided is a method for marking a product for human or animal use with an XRF identifiable mark, the method including forming on at least a region of the product a pattern of at least one FDA-grade material identifiable by XRF, the pattern being optionally at least partially invisible to the naked human eye and having a predefined identifiable characteristic, wherein the product is selected from food products, therapeutics and cosmetics.

A functional water containing a polyfunctional amine and/or a salt thereof as a functional component, wherein the total content of water, the polyfunctional amine, and the salt of the polyfunctional amine is 95% by weight or more. The polyfunctional amine is at least a specific polyamine, a polymer having a structural unit derived from a specific cyclic amine, or a polymer having a structural unit derived from a specific unsaturated amine. The total content of the polyfunctional amine and/or salt thereof is preferably 0.0001 to 10000 ppm by weight. The functional water has functions including freshness-keeping for foods, aging of foods, antisepsis, deodorization, adjustment of plant growth, life extension for cut flowers, flowering control for cut flowers, pest control, pest repellence, improvement of bowel movement, reduction of fecal odor, reduction of blood pressure, increase of body temperature, improvement of the intraoral environment, prevention of halitosis, and prevention of body odor.

The present application relates to use of cysteine or a salt thereof for the protection, growth acceleration and/or stability improvement of lactic acid bacteria.

Disclosed herein are stabilized powder and aqueous formulations comprising a phospholipid comprising omega fatty acid and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations thereof, wherein the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 6 months or at least 12 months; and methods for preparing these formulations.